Benzinga | Aug 27, 2020 04:11PM EDT

Okta Therapeutics Sees Total Revs. $202M To $203M; Sees Non-GAAP Operating Loss Of $(3M) To $(2M); Sees Non-GAAP Net Loss Per Share Of $(0.02) To $(0.01)

For the third quarter of fiscal 2021, the Company expects:

* Total revenue of $202 million to $203 million, representing a growth rate of 32% to 33% year-over-year

* Non-GAAP operating loss of $3.0 million to $2.0 million

* Non-GAAP net loss per share of $0.02 to $0.01, assuming weighted shares outstanding of approximately 129 million

For the full year fiscal 2021, the Company now expects:

* Total revenue of $800 million to $803 million, representing a growth rate of 37% year-over-year

* Non-GAAP operating loss of $13.0 million to $11.0 million

* Non-GAAP net loss per share of $0.03 to $0.01, assuming weighted shares outstanding of approximately 127 million